ClinicalTrials.gg
CompletedNCT05861349Updated May 6, 2024

Median Nerve Stenosis in Carpal Tunnel Syndrome

An observational study in Carpal Tunnel Syndrome, sponsored by Jakub Antczak. Completed at 1 site in Poland. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-06.

Sponsored by Jakub Antczak · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
84
Ages
18 Years to 85 Years
Sex
All
01

Study summary

The goal of this observational study is to test the new kind of ultrasound-based measurements in patients with carpal tunnel syndrome. The main questions it aims to answer are:

  • Do the measurements of the size of the median nerve at the point where it is maximally compressed accurately diagnose carpal tunnel syndrome?
  • May these measurements accurately tell how severe is the carpal tunnel syndrome?

Participants will be asked to:

  • Undergo conduction studies of median and ulnar nerve.
  • Undergo ultrasound of the median nerve.
  • Fill out the Boston carpal tunnel questionnaire and a demographic questionnaire.

Researchers will compare the group of patients with carpal tunnel syndrome with healthy volunteers to see if respective measurements differ significantly between groups.

Read the detailed description

Carpal tunnel syndrome (CTS) is the most common compression neuropathy. CTS results from the compression of the median nerve in the carpal tunnel. The main symptoms include pain and other unpleasant sensations in hand and wrist. In more advanced stage, weakness and wasting of the thenar and other muscles innervated by median nerve occurs, which may lead to permanent impairment of manual performance. Nerve conduction studies (NCS) remain the method of choice in diagnosing CTS. However ultrasonography (US) is increasingly used along with or instead of NCS. Most frequently, the increase of the cross-sectional area of the median nerve at the inlet to the carpal tunnel is regarded as the marker of CTS. A number of other measurements such as median nerve mobility, volar bulging of flexor retinaculum and others were also studied to increase diagnostic sensitivity and specificity. In this study the investigators aim to assess the utility of measurements made at the point of the maximal stenosis of the median nerve in the tunnel to diagnose CTS. So far, there were only few studies, which visualized the maximal nerve stenosis, which is the essential pathological feature of CTS. In general, the group of patients with CTS and controls will undergo NCS of symptomatic median and ipsilateral ulnar nerves and US of the symptomatic median nerve with measurements of the cross-sectional area, diameter and echogenicity at various points, including the point of the maximal stenosis. The location of the maximal stenosis with respect to external (distal crease) and internal (wrist and hand bones and thenar musculature) will also be evaluated. Subjects will also be asked to fill out the Boston Carpal Tunnel Questionnaire (BCTQ) and a demographic questionnaire. US measurements will be compared between patients and healthy volunteers. US measurements, especially those made at the point of stenosis will be correlated among patients with clinical severity of CTS, reflected by the score in BCTQ and with the grade of electrophysiological severity as introduced by Padua et al. [1].

02

Conditions studied

  • Carpal Tunnel Syndrome

Keywords

  • Carpal Tunnel Syndrome
  • ultrasound
  • nerve compression
03

In context

Carpal Tunnel Syndrome

591 studies on the registry are indexed under Carpal Tunnel Syndrome; 133 are open to participants now.

This study's enrollment of 84 is close to the median of 92 across 131 observational studies indexed under Carpal Tunnel Syndrome.

Browse Carpal Tunnel Syndrome studies →

Lead sponsor

Jakub Antczak is the lead sponsor of 8 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Participants will be recruited from the patients referred to the EMG Laboratory of the Department of Neurology at Jagiellonian University Medical College for verification of clinical diagnosis of CTS. After NCS and/or US confirms the CTS, the patient will be asked if she/he would like to take part in the study. Healthy controls will be recruited from the patients referred for verification of clinical diagnosis of tetany, after EMG reveals weak tetany or does not confirm it.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Symptoms of CTS
  • Electrophysiologic and/or ultrasonographic confirmation of CTS diagnosis

Exclusion criteria

Exclusion Criteria:

  • Psychiatric or cognitive conditions with may disturb participation in the study
  • Peripheral neuropathy in history
  • Fractures and severe trauma in the area of the wrist in history
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
84 participants (actual)
Patient registry
No

Groups and cohorts

  • Patients with CTS

    Patients referred to the Electromyographic Laboratory of the Department of Neurology at the Jagiellonian University Medical College, Cracow, Poland with symptoms suggestive of CTS (numbness of the hand, present or accentuated in the night, reduced hand dexterity) with CTS confirmed in NCS or US.

    Diagnostic Test: Nerve conduction study · Diagnostic Test: Ultrasound

  • Healthy controls

    Subjects referred to the Electromyographic Laboratory of the Department of Neurology at the Jagiellonian University Medical College, Cracow, Poland for investigation towards tetany, with no or only weak signs of tetany in electromyography.

    Diagnostic Test: Nerve conduction study · Diagnostic Test: Ultrasound

Interventions

  • Diagnostic testNerve conduction study

    Nerve conduction study of median and ulnar nerve together with sensory comparative methods on the affected side (sides).

  • Diagnostic testUltrasound

    Ultrasound of the median nerve on the affected side (sides).

06

What researchers measure

Primary outcomes

  1. Difference in the diameter of median nerve in the site of its maximal compression

    Difference in the diameter of median nerve in the site of its maximal compression between patients with CTS and healthy controls.

    Time frame: Through study completion, an average of 1 year.

  2. Difference in the cross-sectional area of median nerve in the site of its maximal compression

    Difference in the cross-sectional area of median nerve in the site of its maximal compression between patients with CTS and healthy controls.

    Time frame: Through study completion, an average of 1 year.

  3. Difference in the echogenicity of median nerve in the site of its maximal compression

    Difference in the echogenicity of median nerve in the site of its maximal compression between patients with CTS and healthy controls.

    Time frame: Through study completion, an average of 1 year.

Secondary outcomes

  1. Correlation of the diameter of median nerve in the site of its maximal compression with BCTQ score

    Correlation of the diameter of median nerve in the site of its maximal compression with BCTQ score in patients with CTS.

    Time frame: Through study completion, an average of 1 year.

  2. Correlation of the cross-sectional area of median nerve in the site of its maximal compression with BCTQ score

    Correlation of the cross-sectional area of median nerve in the site of its maximal compression with BCTQ score in patients with CTS.

    Time frame: Through study completion, an average of 1 year.

  3. Correlation of echogenicity of median nerve in the site of its maximal compression with BCTQ score

    Correlation of echogenicity of median nerve in the site of its maximal compression with BCTQ score in patients with CTS.

    Time frame: Through study completion, an average of 1 year.

  4. Correlation of the diameter of median nerve in the site of its maximal compression with CTS electrophysiological severity grade

    Correlation of the diameter of median nerve in the site of its maximal compression with CTS electrophysiological severity grade in patients with CTS.

    Time frame: Through study completion, an average of 1 year.

  5. Correlation of the cross-sectional area of median nerve in the site of its maximal compression with CTS electrophysiological severity grade

    Correlation of the cross-sectional area of median nerve in the site of its maximal compression with CTS electrophysiological severity grade in patients with CTS.

    Time frame: Through study completion, an average of 1 year.

  6. Correlation of echogenicity of median nerve in the site of its maximal compression with CTS electrophysiological severity grade

    Correlation of echogenicity of median nerve in the site of its maximal compression with CTS electrophysiological severity grade in patients with CTS.

    Time frame: Through study completion, an average of 1 year.

07

Study locations

1 site
  • Jagiellonian University Medical College, Department of Neurology
    Kraków, Lesser Poland 31503, Poland
08

References and documents

Publications

  • Padua L, LoMonaco M, Gregori B, Valente EM, Padua R, Tonali P. Neurophysiological classification and sensitivity in 500 carpal tunnel syndrome hands. Acta Neurol Scand. 1997 Oct;96(4):211-7. doi: 10.1111/j.1600-0404.1997.tb00271.x. PubMed 9325471 ↗

Individual participant data

Plan to share: Yes — After completing the study, the age and gender of participants as well as the scores of BCTQ, the results of NCS and the US images in .jpg and .dicom will be available to other researchers on request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: The data will become available after the study results will be published.

Access criteria: On request sent by e-mail to jakub.antczak@uj.edu.pl

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Feb 2024, 3 months.

Of 40 non-industry observational studies under Carpal Tunnel Syndrome, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 44. This study's 3 months is below that.

Counting every sponsor, half of 42 studies reached it within 18 months; a quarter within 11 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2023
First posted
May 16, 2023
StartActual
Nov 1, 2023
Primary completionActual
Feb 29, 2024
CompletionActual
May 3, 2024
Last update
May 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05861349
Lead sponsor
Jakub Antczak
Responsible party
Jakub Antczak (Principal Investigator, Jagiellonian University) — Sponsor-investigator
First posted
May 16, 2023
Start date
Nov 1, 2023
Primary completion
Feb 29, 2024
Completion
May 3, 2024
Last update
May 6, 2024

Study contacts

Agnieszka M Fryźlewicz, MD
study director · Jagiellonian University Medical College, Department of Neurology
Gabriela G Rusin, MD
study chair · Jagiellonian University Medical College, Department of Neurology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion